The latest episode of STAT’s weekly biotech podcast, The Readout LOUD, covers two distinct threads: the nomination of Heidi Overton to lead the FDA and the rise of Chinese drug development. According to the episode description, correspondent Jason Mast joins from Shanghai, where he is examining what China’s expanding biotech industry means for the broader drug development landscape.
The other major topic is Overton, described as the president’s pick to be FDA commissioner. The hosts ask whether she will bring needed stability or controversy to the agency, though the episode description does not go into detail on her record or positions. Instead, it points listeners to separate STAT articles for more on Overton’s views on China.
Because the source is a podcast summary, it offers little substance on the merger between ITM and Telix or the osteoporosis update it mentions. Those items appear only as links to other coverage. The episode is best understood as a roundup, with the Shanghai reporting and the Overton nomination as the two headline subjects.